Statin initiation following coronary artery bypass grafting: Outcome of a hospital discharge protocol

Chest

Volumn 127, Issue 2, 2005, Pages 455-463

  Khanderia, Ujjaini ^a,d   Townsend, Kevin A ^a   Eagle, Kim ^b,c   Prager, Richard ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clinical protocols; Coronary artery bypass; Guideline adherence; Hydroxymethylglutaryl coenzyme A reductase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG TOLERABILITY; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MALE; PATIENT MONITORING; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 13644260693     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.2.455     Document Type: Article

References (37)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307
3. Sacks FM, Braunwald E, Davis BR, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial. N Engl J Med 1996; 335:1001-1009
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622
5. Long-term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357
6. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360:7-22
7. Sever PS, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandanavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003; 361:1149-1158
8. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999; 39:111-118
9. Barbir M, Hunt BJ, Galloway D, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol 1994; 17:59-64
10. Nwasokwa ON. Coronary artery bypass graft disease. Ann Intern Med 1995; 123:528-545
11. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97:916-931
12. Daida H, Yokoi H, Miyano H, et al. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 1995; 25:193-197
13. Lie JT, Lawrie GM, Morris GL. Aortocoronary bypass saphenous vein atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol 1977; 40:906-914
14. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-1332
15. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti-coagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162
16. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240
17. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990; 264:3013-3017
18. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82:61-65
19. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choleterol goals. Arch Intern Med 2000; 160:459-467
20. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001; 87:819-822
21. Muhlestein JB, Horne BD, Blair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87:257-261
22. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 34:1262-1347
23. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285:2486-2497
24. Khanderia U, Faulkner TV, Townsend KA, et al. Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting. Am J Health Syst Pharm 2002; 59:548-551
25. Northridge DB, Shandall A, Rees A, et al. Inadequate measurement of hyperlipidemia after coronary bypass surgery shown by medical audit. Br Heart J 1994; 72:466-467
26. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease; principal results. Eur Heart J 1997; 18:1569-1582
27. Lacy CR, Suh DC, Barone JA, et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 2002; 162:468-473
28. Landymore RW. Inaccuracy of serum lipid measurements after open heart operations. Can J Cardiol 1991; 7:24-26
29. Lipitor [package insert]. New York, NY: Pfizer, 2002
30. Zocor [package insert]. Whitehouse Station, NJ: Merck and Co, 2004
31. Lescol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, 2003
32. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceutical, 2003
33. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103:38-44
34. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691-696
35. Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003; 163:2576-2582
36. Birtcher KK, Bowden C, Ballantyne CM, et al. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol 2000; 85:30A-35A
37. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the guidelines applied in practice (GAP) initiative. JAMA 2002; 287:1269-1276